Immune Pharmaceuticals Inc (IMNP) financial statements (2022 and earlier)

Company profile

Business Address 1 BRIDGE PLAZA N, SUITE 270
FORT LEE, NJ 07024
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments761,5082,7346,7767622111
Cash and cash equivalents761,5082,7346,7767622111
Restricted cash and investments      25
Other current assets288230215255348231353
Total current assets:3641,7382,9497,031424253489
Noncurrent Assets
Property, plant and equipment976131 5858326
Intangible assets, net (including goodwill)5,1555,3636,2476,4776,7076,9632,729
Intangible assets, net (excluding goodwill)5,1555,3636,2476,4776,7076,9632,729
Regulated entity, other noncurrent assets     200300
Other noncurrent assets100100100100121122340
Other undisclosed noncurrent assets15,00015,00015,00015,00015,00014,80014,700
Total noncurrent assets:20,35220,52421,37821,57721,88622,14318,395
TOTAL ASSETS:20,71622,26224,32728,60822,31022,39618,884
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,2145,4975,9505,6898,2426,8015,944
Accounts payable5,5353,5973,6833,5696,6144,5073,736
Accrued liabilities1,6791,9002,2672,1201,6282,2942,208
Debt7,4626,8643,1723,2965,5197,3811,952
Due to related parties186232274266305236236
Total current liabilities:14,86212,5939,3969,25114,06614,4188,132
Noncurrent Liabilities
Long-term debt and lease obligation8708701,4341,4571,7382,1761,059
Long-term debt, excluding current maturities8708701,4341,4571,7382,1761,007
Capital lease obligations      52
Liabilities, other than long-term debt4,1424,1424,1424,1425,9335,9335,933
Deferred tax liabilities, net4,1424,1424,1424,1425,9335,9335,933
Total noncurrent liabilities:5,0125,0125,5765,5997,6718,1096,992
Total liabilities:19,87417,60514,97214,85021,73722,52715,124
Stockholders' equity
Stockholders' equity attributable to parent8424,6579,35513,758573(131)3,760
Common stock4432111
Additional paid in capital127,607127,290127,272127,292110,959104,204103,159
Accumulated deficit(126,769)(122,637)(117,920)(113,536)(110,387)(104,336)(99,400)
Total stockholders' equity:8424,6579,35513,758573(131)3,760
TOTAL LIABILITIES AND EQUITY:20,71622,26224,32728,60822,31022,39618,884

Income statement (P&L) ($ in thousands)

9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
Revenues   (100)   
Operating expenses(3,698)(2,843)(4,326)(3,805)(2,839)(2,784)(2,695)
Operating loss:(3,698)(2,843)(4,326)(3,805)(2,839)(2,784)(2,695)
Nonoperating income (expense)(434)(1,874)(58)(293)278(10)(3)
Other nonoperating income (expense)55(21)(19)(293)278(10)(3)
Interest and debt expense(498)181(65)982(3,585)(2,142)(1,055)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes498(181)65(2,006)95  
Loss from continuing operations before income taxes:(4,132)(4,717)(4,384)(5,122)(6,051)(4,936)(3,753)
Other undisclosed income from continuing operations   1,973   
Net loss attributable to parent:(4,132)(4,717)(4,384)(3,149)(6,051)(4,936)(3,753)
Other undisclosed net loss available to common stockholders, basic(5,541)(5,599) (6,864)   
Net loss available to common stockholders, diluted:(9,673)(10,316)(4,384)(10,013)(6,051)(4,936)(3,753)

Comprehensive Income ($ in thousands)

9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
Net loss:(4,132)(4,717)(4,384)(3,149)(6,051)(4,936)(3,753)
Comprehensive loss, net of tax, attributable to parent:(4,132)(4,717)(4,384)(3,149)(6,051)(4,936)(3,753)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: